<DOC>
	<DOCNO>NCT00985959</DOCNO>
	<brief_summary>The purpose study Phase I select recommend dose bortezomib combination melphalan prednisolone Japanese participant . In Phase II , ass effectiveness safety recommend dose bortezomib ( select phase I portion ) .</brief_summary>
	<brief_title>A Study JNJ-26866138 ( Bortezomib ) Untreated Multiple Myeloma Patients Who Are Not Candidates Hematopoietic Stem Cell Transplant ( HSCT )</brief_title>
	<detailed_description>This open-label ( physician participant know intervention ) , non-randomized ( participant assign chance ) , multi-center study untreated multiple myeloma participant candidate hematopoietic stem cell transplant . This study consist two part : Phase I Phase II . In Phase I , total 18 participant enrol ie , 6 patient per dose level ( 0.7 , 1.0 1.3 mg/m2 ) determine recommend dose bortezomib . In Phase II , additional 83 participant enrol . Safety evaluation include assessment adverse event , clinical laboratory test , specifically hematological toxicity .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Participants diagnose symptomatic nonsecretory multiple myeloma Participants receive chemotherapy hematopoietic stem cell transplantation candidate Participants measurable lesion Life expectancy great equal 3 month Previously receive treatment Multiple Myeloma Greater equal Grade 2 peripheral neuropathy neuropathic pain Myocardial infarction within 6 month prior enrollment uncontrolled angina , severe uncontrolled ventricular arrhythmia , clinically significant conduction system abnormalities Patient know seropositive human immunodeficiency virus ( HIV ) , Hepatitis B surface antigenpositive active hepatitis C infection Active prior malignancy diagnose within last 5 year Female participant pregnant breastfeeding Participant enrol another clinical research study and/or receive investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Multiple myeloma</keyword>
	<keyword>Hematopoietic stem cell transplant</keyword>
	<keyword>HSCT</keyword>
	<keyword>Melphalan</keyword>
	<keyword>Prednisolone</keyword>
	<keyword>Bortezomib</keyword>
	<keyword>JNJ-26866138</keyword>
</DOC>